Companies: 10,795·Total market cap: $144.5T
BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.

BRTXNASDAQHealthcare● Active
$0.39
+$0.02(+6.80%)
Market Cap$3476501
P/E Ratio
52W High$2.045
52W Low$0.1593
SEC Filings

BioRestorative Therapies, Inc. (BRTX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001505497 · BRTX · NASDAQ · as of Jun 10, 2026

Filing snapshot

736
Total Filings
8-K
Latest Form
2026-05-29
Most Recent
2012
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001505497 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-26
Fiscal Year End
Mar 26, 2026
Accession No.
0001493152-26-012925
Primary Document
form10-k.htm
Source: data.sec.gov · CIK 0001505497 · Accession 0001493152-26-012925

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-14
8-KCurrent Report
FORM 8-K DATED MARCH 26, 2026
2026-05-29Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
FORM 8-K DATED MARCH 26, 2026
2026-05-29
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-14
View
8-KCurrent Report
CURRENT REPORT FILING
2026-05-01
View
424B3424B3
424B3
2026-04-30
View
EFFECTEFFECT
EFFECT
2026-04-28
View
POS AMPOS AM
POS AM
2026-04-27
View
8-KCurrent Report
CURRENT REPORT FILING
2026-04-23
View
POS AMPOS AM
POS AM
2026-04-20
View
DEF 14AProxy Statement
Proxy Statement
2026-04-13
View
PRE 14APRE 14A
PRELIMINARY PROXY STATEMENT NOT RELATED TO A CONTESTED MATTER OR MERGER/ACQUISIT
2026-04-03
View
10-KAnnual Report
10-K
2026-03-26
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-23
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-02-18
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
Showing 1–15 of 472 filingsForm 4 / 144 hidden· 736 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001505497  |  Exchange: NASDAQ · Healthcare

BioRestorative Therapies, Inc. (NASDAQ: BRTX) has submitted 736 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2012. As a Healthcare sector company with CIK 0001505497, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is BioRestorative Therapies, Inc.'s most comprehensive regulatory disclosure. The most recent BioRestorative Therapies, Inc. 10-K was filed on 2026-03-26 for fiscal year ending 2026. Historical BRTX 10-K annual reports are available from 2010 through 2026.

Investors researching BioRestorative Therapies, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-10

Frequently Asked Questions

BRTX SEC Filings · 8 questions

BioRestorative Therapies, Inc. (BRTX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 736 filings and access original documents at no cost. BioRestorative Therapies, Inc.'s CIK is 0001505497.

BRTX SEC filingsBioRestorative Therapies, Inc. SEC documentsfind BRTX 10-K